Incadronate inhibits osteoporosis in ovariectomized rats

European Journal of Pharmacology

Volumn 457, Issue 1, 2002, Pages 51-56

  Teramura, Kyoko ^a,b   Fukushima, Shinji ^a   Iwai, Takaya ^a   Nozaki, Kazutoshi ^a   Kokubo, Satoshi ^a   Takahashi, Koichiro ^a  

^a INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Bisphosphonate; Bone mineral density; Deoxypyridinoline; Osteoporosis; Ovariectomy

Indexed keywords

DEOXYPYRIDINOLINE; INCADRONIC ACID; OSTEOCALCIN; AMINO ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE;

ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MINERAL; COMPRESSIVE STRENGTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FEMUR; LUMBAR VERTEBRA; METAPHYSIS; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; URINE LEVEL; ANIMAL; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; URINE;

ADMINISTRATION, ORAL; AMINO ACIDS; ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPRESSIVE STRENGTH; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; OSTEOCALCIN; OSTEOPOROSIS; OVARIECTOMY; PARATHYROID HORMONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0037073607     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02659-6     Document Type: Article

References (23)

1. Abe T., Flanagan A.M., Chambers T.J. Comparative studies of actions of bisphosphonates on bone resorption in vitro. J. Bone Miner. Res. 5(Suppl. 2):1990;S86.
2. Black D., Duncan A., Robins S.P. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high performance liquid chromatography. Anal. Biochem. 169:1988;197-203.
3. Christenson R.H. Biochemical markers of bone metabolism: an overview. Clin. Biochem. 30:1997;573-593.
4. Delmas P.D. Biochemical markers of bone turnover. J. Bone Miner. Res. 8:1993;s549-s555.
5. Dempster D.W., Lindsay R. Pathogenesis of osteoporosis. Lancet. 341:1993;797-805.
6. Fujimoto R., Nii A., Okazaki A., Miki H., Kawashima H. Effect of disodium dihydrogen (cycloheptylamino) methylene bisphosphonate monohydrate (YM175) on the bone formation and resorption in rats and dogs: histological examination. J. Bone Miner. Res. 5(Suppl. 2):1990;S157.
7. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1995;1478-1487.
8. Kawamuki K., Abe T., Kudo M., O'uchi N., Motoie H., Isomura Y., Takeuchi M., Kawashima H., Murase K. Pharmacological actions of the novel bisphosphonate YM175. Recent Prog. Osteoporos. Res. 5:1990;132-137.
9. Kudo M., Abe T., Kawamuki K., Yamaoka E., Isomura Y., Takeuchi M., Kawashima H. Effect of YM175 on experimental hypercalcemia and tumor-induced osteolysis in rats. J. Bone Miner. Res. 5(Suppl. 2):1990;S166.
10. Motoie H., Nakamura T., O'uchi N., Nishikawa H., Kanoh H., Abe T., Kawashima H. Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J. Bone Miner. Res. 10:1995;910-920.
11. Motoie H., Kanoh H., Ogata S., Kawamuki K., Shikama H., Fujikura T. Prevention of bone loss by bisphosphonate YM175 in ovariectomized dogs with dietary calcium restriction. Jpn. J. Pharmacol. 71:1996;239-246.
12. Motoie H., Okazaki A., Kanoh H., Shikama H., Fujikura T. Increase of bone mass and mechanical strength in rats after treatment with a novel bisphosphonate YM175, for 2 years. Pharmacol. Toxicol. 81:1997;42-47.
13. Price P.A., Parthemore J.G., Deftos L.J., Nishimoto S.K. New biochemical marker for bone metabolism. J. Clin. Invest. 66:1980;878-883.
14. Price P.A., Williamson M.K., Lothringer J.W. Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J. Biol. Chem. 256:1981;12760-12766.
15. Riggs B.L., Melton I.J. III Involutional osteoporosis. N. Engl. J. Med. 314:1986;1676-1686.
16. Robey P.G. The biochemistry of bone. Metabolic bone disease, part I. Endocrinol. Metab. Clin. N. Am. 18:1989;859-902.
17. Selander K.S., Monkkonen J., Karhukorpi E.K., Harkonen P., Hannuniemi R., Vaananen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50:1996;1127-1138.
18. Takahashi K., Shirahata A., Fukushima S., Kokubo S., Teramura K., Usuda S. Effects of YM175, a new-generation bisphosphonate, on hypercalcemia induced by tumor-derived bone resorbing factors in rats. Jpn. J. Pharmacol. 76:1998;155-163.
19. Takeuchi M., Sakamoto S., Yoshida M., Abe T., Isomura Y. Studies on novel bone resorption inhibitors: Part I. Synthesis and pharmacological activities of aminomethylene bisphosphonate derivatives. Chem. Pharm. Bull. 41:1993;688-693. (Tokyo).
20. Tanaka S., Hiraga T., Ozawa Y., Teramura K., Motoie H., Tanaka T., Yamamoto M. YM175 inhibits tumor-induced osteolysis in nude mice with bone metastases. J. Bone Miner. Res. 10(Suppl. 1):1995;262.
21. Uebelhart D., Gineyts E., Chapuy M.C., Delmas P.D. Urinary excretion of pyridinium crosslinks. A new marker of bone resorption in metabolic bone disease. Bone Miner. 8:1990;87-96.
22. Usui T., Watanabe T., Higuchi S. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab. Dispos. 23:1995;1214-1219.
23. Yeh J.K., Aloia J.F., Chen M. Growth hormone administration potentiates the effect of treadmill exercise on long bone formation but not on the vertebrae in middle-aged rats. Calcif. Tissue Int. 54:1994;38-43.